This post originally appeared on Business Insider.
Theranos CEO Elizabeth Holmes has said the company will publish its data to the public to prove the accuracy of its blood tests, the New York Times reports.
“Data is a powerful thing because it speaks for itself,” she said at a conference Monday night, according to the Times.
The about-face comes after The Wall Street Journal published a five-month investigation from John Carreyrou that questioned just how revolutionary the startup was, specifically regarding the use of the Edison technology the company says can reveal extensive medical information from a single drop of blood.
During a period last year reviewed by The Journal, the newspaper reported, only 10 percent of the tests that Theranos carried out used the new technology, something the company did not publicly disclose, and the results sometimes varied wildly from those of more traditional tests.
Holmes did not publish data for peer review, the traditional process for evaluating medical technology.
“I just always believed that as the FDA decision summaries came out one by one with our data, that actually that would be so much more transparent a model” than making the company’s data available for peer review, Holmes said at the conference sponsored by the Cleveland Clinic.
Walgreens, the biggest partner of Theranos through its Wellness Centers, has taken a step back from the company, halting cooperation until questions have been answered about the technology. The drugs giants Pfizer and GlaxoSmithKline, both of which had reportedly worked with Theranos, have denied having any ties with the company.
Beyond making the data available, Theranos also appears to be preparing for a legal fight, adding David Boies, the well-known lawyer who was working as an outside counsel, to its board of directors.
See also: Here’s What It’s Really Like to Get Blood Drawn at Theranos
